A depot GnRH agonist; same flare-then-suppression mechanism as leuprolide. Structurally it is GnRH receptor agonist (decapeptide analog).

How strong is the evidence for Goserelin?

PeptideHormone grades Goserelin at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.

What is the half-life of Goserelin?

The reported circulating half-life of Goserelin is ~4–5 h (implant depot).

Is Goserelin FDA-approved?

Yes — as of September 2026, Goserelin is an approved prescription medicine in the United States. Zoladex implant approved for prostate and breast cancer and endometriosis. Status is US-centric and can change; check the FDA record for the current position.

Is Goserelin the same as Zoladex?

Zoladex is a brand name of Goserelin — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

Goserelin

A depot GnRH agonist; same flare-then-suppression mechanism as leuprolide.

Also known as Zoladex.

AnalogEstablishedFDA-approvedBased on Gonadotropin-releasing hormoneCompare with GnRH Compare lineage

The same inversion in depot form: continuous stimulation as a means of suppression, delivered on a schedule a body can keep.

Identity

Class: GnRH receptor agonist (decapeptide analog)
Source: Synthetic analog of GnRH
Receptor: GnRH receptor (GnRHR)

Key properties

Evidence floorClinicalREF1CLIN1

Molecular weight

~1,269.4 Da

REF

Half-life (native)

~4–5 h (implant depot)

CLIN

Model dosing

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

Goserelin is a GnRH agonist delivered as a slow-release implant. Like other agonists, continuous exposure desensitizes the GnRH receptor after an initial flare, producing sustained suppression of the gonadotropins and downstream sex steroids.

Reference notes

Delivered as a subcutaneous depot implant for steady, long-term exposure.
Shares the agonist flare-then-desensitization mechanism with leuprolide.
Illustrates the pulsatility principle: continuous GnRH signaling suppresses the axis.

Regulatory status

United States · reviewed September 2026

FDA-approvedGoserelin is an approved prescription medicine in the United States.

Basis: Zoladex implant approved for prostate and breast cancer and endometriosis.

Status describes the molecule as a drug substance under US law and is an editorial reading of the public record — approvals, trial registrations, and the FDA 503A bulk-substances list. It is not legal advice and it changes; the review date above is the last time the table was checked. Other jurisdictions are noted only where they differ materially.

Common questions

What is Goserelin?: A depot GnRH agonist; same flare-then-suppression mechanism as leuprolide. Structurally it is GnRH receptor agonist (decapeptide analog).
How does Goserelin work?: Goserelin is a GnRH agonist delivered as a slow-release implant. Like other agonists, continuous exposure desensitizes the GnRH receptor after an initial flare, producing sustained suppression of the gonadotropins and downstream sex steroids.
How strong is the evidence for Goserelin?: PeptideHormone grades Goserelin at the "Established" evidence tier — its mechanism and core effects are settled across the peer-reviewed literature. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of Goserelin?: The reported circulating half-life of Goserelin is ~4–5 h (implant depot).
Is Goserelin FDA-approved?: Yes — as of September 2026, Goserelin is an approved prescription medicine in the United States. Zoladex implant approved for prostate and breast cancer and endometriosis. Status is US-centric and can change; check the FDA record for the current position.
Is Goserelin the same as Zoladex?: Zoladex is a brand name of Goserelin — the same molecule in different approved presentations. This page is the molecule reference, not a prescribing guide.

In the literature

Live registry counts · retrieved 2026-09-15

Registered trialsREF

37044 recruiting

Ph 134
Ph 2162
Ph 3114
Ph 422

Open on ClinicalTrials.gov

Searched as Goserelin, Zoladex. Counts are search hits from the primary registries, not a curated set and not a grade – a measure of how much work exists on Goserelin, not how it turned out.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

1.Goserelin · , 2012 · PMID 31644049
2.Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials · The Lancet. Oncology, 2022 · PMID 35123662

External references

Goserelin in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.